The Conversation (0)
Alchemia Limited (ASX:ACL) announced that it has been awarded a key US patent for its HyACT Targeted Chemotherapy, which is critical to the company’s platform oncology technology.
Alchemia Limited (ASX:ACL) announced that it has been awarded a key US patent for its HyACT Targeted Chemotherapy, which is critical to the company’s platform oncology technology.
As quoted in the press release:
The US patent, number 8,388,993, is regarded as a critical development milestone for the company and provides US protection for the use of the company’s proprietary drug HA-Irinotecan in the treatment of metastatic colorectal cancer. This drug is currently being evaluated in more than 400 patients in a pivotal phase III clinical trial at 76 sites globally.
Click here to read the full Alchemia Limited (ASX:ACL) press release.
